RE: Questions and answers19 Dec 2025 11:45
Here4Hemo Great Post below
A very interesting RNS and one that raised a few questions for me.
Why was it that one of our largest shareholders and a high net worth individual was happy to put his hand in his pocket again and add to his already sizeable holding?
And why was it that Vlad, as per my understanding, turned down broker financing that was on offer?
And for that matter, why was Vlad happy to extend his financial runway until March when he could have easily extended it further by asking other long term holders to exercise their warrants as well?
Well it could be he’s confident of Janus sub letting their laboratory and extending the runway further.
Or it could be that he’s confident of securing a multi million dollar partnership and royalty deal for CDX.
Or maybe he’s on the verge of a deal to spin off CBR.
It could be he’s confident of agreeing a Master Service Agreement with Cellin and the Estonian government to secure first commercial revenue for HG-CT-1 in Estonia and ultimately Europe.
Or maybe it’s because he knows the technology transfer will be completed for Made Scientific.
Or that he now has the funds to treat both patient four with an escalated dose and patient one, a child from the pediatric ward of MDA.
But then I think whilst all of the above are likely to increase the SP, some of them substantially, none of them really address the finances required to complete Phase One of the HG-CT-1 trials, so I asked myself the same question again, why was Vlad happy to have an initial financial runway until March?
My conclusion is this. By March Vlad should have most if not all the above ticked off. What this would mean is he’d have ring fenced CBR and added value to Hemogenyx by having two viable product candidates rather than one. Furthermore, HG-CT-1 would have not only the first cohort passing safety with hopefully one patient reaching one year of being alive after being treated, patient four passing 28 safety along with the first child passing 28 safety, obviously all being well.
So I’m thinking maybe getting finance until March isn’t a coincidence. Maybe just maybe it’s a calculated plan and part of Vlads discussions with pharmaceutical companies. Maybe at least one of them would like to purchase Hemogenyx but want to see a patient survive for a year, want to see the first dose escalation pass safety, along with the first child. And maybe this particular company want a ready made manufacturing facility in the states, something that is commercially scalable, highly efficient and cost effective and also desires an early revenue stream from Europe. And maybe with this de-risking they would be willing to pay a substantial premium for the company, which would allow a cash rich Vlad to be happy progressing with just CBR?
These are just my initial thoughts in today’s RNS. As always I’m happy to sit back and see how it all plays out.
Sign In
Follow the stocks
